Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus Actinomycin-D for GTN with FIGO Score 5-6
NCT06028672Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2023
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of toripalimab in gestational trophoblastic neoplasia (GTN) (2 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Complete Remission Rate. Started Sep 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
gestational trophoblastic neoplasia (GTN)
Beyond the preview
Go deeper on NCT06028672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028672.